Clinical trial

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

NCT05020860

Study summary

ClinicalTrials.gov

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

8 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Paclitaxel Normalized identity: paclitaxel View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Carboplatin Normalized identity: carboplatin View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Trastuzumab Normalized identity: trastuzumab View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Pertuzumab Normalized identity: pertuzumab View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Doxorubicin Normalized identity: doxorubicin View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Cyclophosphamide Normalized identity: cyclophosphamide View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Pembrolizumab Normalized identity: pembrolizumab View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Pertuzumab/Trastuzumab/Hyaluronidase-zzxf Find medicine records · Find other trials using this name

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2023-04-18

PhasePHASE2

Conditions

Breast Cancerverified · MONDO: breast cancer

Breast Neoplasmverified · MONDO: breast neoplasm

Breast Cancer Femaleunresolved

Breast Cancer Invasiveunresolved

Breast Cancer Stage IIunresolved

Breast Cancer Stage IIIunresolved

Triple Negative Breast Cancercandidate · MONDO: triple-negative breast carcinoma

Hormone Receptor-positive Breast Cancerverified · MONDO: hormone receptor-positive breast cancer

HER2-positive Breast Cancercandidate · MONDO: HER2 positive breast carcinoma

Triple Negative Breast Neoplasmsunresolved

Estrogen Receptor-positive Breast Cancercandidate · MONDO: estrogen-receptor positive breast cancer

Interventions

PaclitaxelDRUG · verified · RxNorm: paclitaxel

CarboplatinDRUG · verified · RxNorm: carboplatin

TrastuzumabDRUG · verified · RxNorm: trastuzumab

PertuzumabDRUG · verified · RxNorm: pertuzumab

DoxorubicinDRUG · verified · RxNorm: doxorubicin

CyclophosphamideDRUG · verified · RxNorm: cyclophosphamide

PembrolizumabDRUG · verified · RxNorm: pembrolizumab

Pertuzumab/Trastuzumab/Hyaluronidase-zzxfDRUG

Sponsors & collaborators

Baylor Breast Care Centerlead sponsor

Mapped research locations

HoustonTexas, United States2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05020860 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.